v3.26.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Assets    
Cash and cash equivalents $ 22,190,231 $ 14,438,792
Prepaid clinical trial costs 819,721 0
Prepaid expenses and other current assets 549,684 664,685
Total current assets 23,559,636 15,103,477
Non-current prepaid clinical trial costs 0 819,721
Total Assets 23,559,636 15,923,198
us-gaap_ShortTermBorrowings 231,274 406,875
Accounts payable 2,085,268 3,009,074
Accrued clinical expenses 2,675,687 2,582,094
Accrued compensation 408,519 485,899
Other accrued liabilities 718,407 791,611
Total current liabilities 6,119,155 7,275,553
Total Liabilities 6,119,155 7,275,553
Stockholders’ Equity 204,762,072 192,773,942
Common stock, par value of $0.0001; 515,000,000 shares authorized; 12,810,377 and 5,872,865 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 12,348 11,655
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025 0 0
Accumulated deficit (187,333,939) (184,137,952)
Total stockholders' equity 17,440,481 8,647,645
Total Liabilities and Stockholders’ Equity $ 23,559,636 $ 15,923,198